HomeCompaniesIs it possible to sustain this rally? Cytokinetics Incorporated (CYTK) Stock

Is it possible to sustain this rally? Cytokinetics Incorporated (CYTK) Stock

Needham lowered the price target for the Cytokinetics Incorporated (NASDAQ:CYTK) stock to “a Buy”. The rating was released on December 23, 2022, according to finviz. The research report from UBS has initiated the stock to Buy, with a price target set at $80. The stock was initiated by Goldman, who disclosed in a research note on January 28, 2022, to Buy and set the price objective to $74. In their research brief published December 22, 2021, Oppenheimer analysts initiated the Cytokinetics Incorporated stock to Outperform with a price target of $55.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Cytokinetics Incorporated (NASDAQ:CYTK) raised 2.25% to close Tuesday’s market session at $43.15, higher as compared to yesterday’s close. The stock price fluctuated between $41.68 and $43.56 throughout the trading session with the volume trading being 1197866 shares, which represented a significant variation when compared to the three months average volume of 1.13 million shares. The firm’s stock price fluctuated 1.01% within the last five trades and -4.37% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 11.38% in the last 6 months and -8.87% was subtracted to its value over the previous 3 months. CYTK stock is trading at a margin of -0.97%, 3.92% and -1.50% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


As of the close of trading, CYTK deals in the Healthcare domain. The stock is trading -22.67 percent below its 52-week high and 47.47 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 19.81. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Cytokinetics Incorporated’s Profitability and Valuation Ratios Tell Us About the Stock?

The stock’s market cap achieved a total value of $4.10 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 27.65 that mirrors the cost to be found for sales by the market.

Is Insider Trading a Real Thing?

Blum Robert I, the President & CEO at Cytokinetics Incorporated (CYTK) has sold 10,000 shares of firm on Jan 17 at a price of $42.43 against the total amount of $0.42 million. In another inside trade, Malik Fady Ibraham, EVP Research & Development of Cytokinetics Incorporated (NASDAQ:CYTK) sold 4,000 shares of the firm on Jan 12 for a total worth of $0.16 million at a price of $40.47. An inside trade which took place on Jan 04, President & CEO of Cytokinetics Incorporated Blum Robert I sold 10,000 shares of firm against total price of $0.44 million at the cost of $44.24 per share.



Please enter your comment!
Please enter your name here

Recent Post